Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 19/20 | 0.55 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.46 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15525978 | 0.92 | HSP90AB1 (0.59) | HSP90AB1HSP90AA1 | |
| SCHEMBL15525975 | 0.92 | HSP90AA1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL15525969 | 0.87 | HSP90AB1 (0.55) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL15522205 | 0.87 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL28341005 | 0.87 | HSP90AB1 (0.53) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL16569776 | 0.87 | HSP90AB1 (0.54) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL16569778 | 0.86 | HSP90AB1 (0.52) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL16569444 | 0.85 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL16569448 | 0.85 | HSP90AB1 (0.52) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL2814577 | 0.85 | HSP90AB1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210085700-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| EP-3738594-A1 | TARGETED THERAPEUTICS HAVING AN HSP90 LIGAND AS BINDING MOIETY | Madrigal Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10828315-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200316090-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. | 2020-10-08 | — | — | US | disclosed |
| EP-3035938-B1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10722525-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10675360-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| CN-110559446-A | Targeted therapeutics | 马德里加尔制药公司 | 2019-12-13 | — | — | CN | disclosed |
| EP-3466416-A2 | A BINDING MOIETY-DRUG CONJUGATE COMPRISING A HSP90 BINDING MOIETY AND A CYTOTOXIC EFFECTOR MOIETY | Madrigal Pharmaceuticals, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9956293-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170128580-A1 | TARGETED THERAPEUTICS | TARVEDA THERAPEUTICS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9597343-B2 | Targeted therapeutics | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170056510-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-02 | — | — | US | disclosed |
| EP-3035938-A1 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20150139905-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2015038649-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-19 | — | — | WO | disclosed |
| EP-2838909-A2 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013158644-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316090-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AB1 2/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-20210085700-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AB1 2/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-20170128580-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AB1 2/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-20150139905-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AB1 2/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-10675360-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | HSP90AB1 2/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-10722525-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | HSP90AB1 2/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-10828315-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | HSP90AB1 2/4885HSP90AA1 5/4885HSP90B1 3/4885 |
| US-20170056510-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AB1 2/4885HSP90AA1 5/4885HSP90B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.